CA2818428A1 - Assays and biomarkers for lrrk2 - Google Patents
Assays and biomarkers for lrrk2 Download PDFInfo
- Publication number
- CA2818428A1 CA2818428A1 CA2818428A CA2818428A CA2818428A1 CA 2818428 A1 CA2818428 A1 CA 2818428A1 CA 2818428 A CA2818428 A CA 2818428A CA 2818428 A CA2818428 A CA 2818428A CA 2818428 A1 CA2818428 A1 CA 2818428A1
- Authority
- CA
- Canada
- Prior art keywords
- 6alkyl
- methyl
- formula
- certain embodiments
- ylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41820810P | 2010-11-30 | 2010-11-30 | |
US61/418,208 | 2010-11-30 | ||
PCT/US2011/062468 WO2012075046A1 (en) | 2010-11-30 | 2011-11-29 | Assays and biomarkers for lrrk2 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2818428A1 true CA2818428A1 (en) | 2012-06-07 |
Family
ID=45217723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2818428A Abandoned CA2818428A1 (en) | 2010-11-30 | 2011-11-29 | Assays and biomarkers for lrrk2 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2646819A1 (ru) |
JP (1) | JP2014504362A (ru) |
KR (1) | KR20130121903A (ru) |
CN (1) | CN103348243A (ru) |
BR (1) | BR112013013457A2 (ru) |
CA (1) | CA2818428A1 (ru) |
MX (1) | MX2013005801A (ru) |
RU (1) | RU2013129818A (ru) |
WO (1) | WO2012075046A1 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20150153A1 (es) | 2012-06-29 | 2015-02-05 | Pfizer | 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 |
WO2014059052A1 (en) * | 2012-10-09 | 2014-04-17 | Uab Research Foundation | Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism |
US9582909B2 (en) * | 2012-11-15 | 2017-02-28 | Shimadzu Corporation | Chromatograph mass spectrometry data processing device |
US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
EP3350178B1 (en) | 2015-09-14 | 2021-10-20 | Pfizer Inc. | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors |
US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
CN105331721A (zh) * | 2015-11-27 | 2016-02-17 | 首都医科大学宣武医院 | 检测pd致病基因突变的方法,及其引物、试剂盒 |
US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
WO2017218843A1 (en) | 2016-06-16 | 2017-12-21 | Denali Therapeutics Inc. | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
RU2761436C1 (ru) | 2017-11-17 | 2021-12-08 | Целликс Био Прайвет Лимитед | Композиции и способы лечения нарушений со стороны органа зрения |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007261095A1 (en) | 2006-06-20 | 2007-12-27 | Novartis Ag | Biomarkers for the progression of Alzheimer's disease |
WO2008091799A2 (en) * | 2007-01-22 | 2008-07-31 | The Trustees Of Columbia University In The City Of New York | Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants |
GB0706709D0 (en) * | 2007-04-05 | 2007-05-16 | Medical Res Council | Methods |
US20100175140A1 (en) * | 2008-12-19 | 2010-07-08 | The Johns Hopkins University | Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies |
WO2010129053A2 (en) * | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
US8367349B2 (en) * | 2010-04-19 | 2013-02-05 | Medical Research Council | Methods for identifying modulators of LRRK2 |
-
2011
- 2011-11-29 BR BR112013013457A patent/BR112013013457A2/pt not_active IP Right Cessation
- 2011-11-29 RU RU2013129818/15A patent/RU2013129818A/ru not_active Application Discontinuation
- 2011-11-29 JP JP2013542113A patent/JP2014504362A/ja active Pending
- 2011-11-29 CN CN2011800663409A patent/CN103348243A/zh active Pending
- 2011-11-29 KR KR1020137016950A patent/KR20130121903A/ko not_active Application Discontinuation
- 2011-11-29 CA CA2818428A patent/CA2818428A1/en not_active Abandoned
- 2011-11-29 EP EP11793632.8A patent/EP2646819A1/en not_active Withdrawn
- 2011-11-29 WO PCT/US2011/062468 patent/WO2012075046A1/en active Application Filing
- 2011-11-29 MX MX2013005801A patent/MX2013005801A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2013005801A (es) | 2013-07-17 |
EP2646819A1 (en) | 2013-10-09 |
JP2014504362A (ja) | 2014-02-20 |
KR20130121903A (ko) | 2013-11-06 |
BR112013013457A2 (pt) | 2017-07-11 |
WO2012075046A9 (en) | 2012-09-13 |
RU2013129818A (ru) | 2015-01-10 |
WO2012075046A1 (en) | 2012-06-07 |
CN103348243A (zh) | 2013-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2818428A1 (en) | Assays and biomarkers for lrrk2 | |
Tang et al. | Structure-guided mutagenesis reveals a hierarchical mechanism of Parkin activation | |
Yadav et al. | TAOK2 kinase mediates PSD95 stability and dendritic spine maturation through Septin7 phosphorylation | |
Chen et al. | Aggregation of the nucleic acid–binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation | |
Braun et al. | Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly | |
Sivadasan et al. | C9ORF72 interaction with cofilin modulates actin dynamics in motor neurons | |
Chou et al. | GSK3beta-mediated Drp1 phosphorylation induced elongated mitochondrial morphology against oxidative stress | |
Zhang et al. | Sequential phosphorylation of Nedd1 by Cdk1 and Plk1 is required for targeting of the γTuRC to the centrosome | |
Lince-Faria et al. | Spatiotemporal control of mitosis by the conserved spindle matrix protein Megator | |
Ivankovic-Dikic et al. | Pyk2 and FAK regulate neurite outgrowth induced by growth factors and integrins | |
Balestrini et al. | GEMC1 is a TopBP1-interacting protein required for chromosomal DNA replication | |
Xiong et al. | GTPase activity plays a key role in the pathobiology of LRRK2 | |
DeLuca et al. | Temporal changes in Hec1 phosphorylation control kinetochore–microtubule attachment stability during mitosis | |
Solc et al. | Multiple requirements of PLK1 during mouse oocyte maturation | |
Guo et al. | CENP-E–dependent BubR1 autophosphorylation enhances chromosome alignment and the mitotic checkpoint | |
Tang et al. | Netrin-1 mediates neuronal survival through PIKE-L interaction with the dependence receptor UNC5B | |
Yoon et al. | Homer1 promotes dendritic spine growth through ankyrin-G and its loss reshapes the synaptic proteome | |
Penmatsa et al. | Compartmentalized cyclic adenosine 3′, 5′-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains | |
Bentley et al. | Distinct sequence elements of cyclin B1 promote localization to chromatin, centrosomes, and kinetochores during mitosis | |
Carvalhal et al. | The nucleoporin ALADIN regulates Aurora A localization to ensure robust mitotic spindle formation | |
Ehlén et al. | Proper chromosome alignment depends on BRCA2 phosphorylation by PLK1 | |
Song et al. | Dynamic crotonylation of EB1 by TIP60 ensures accurate spindle positioning in mitosis | |
Tan et al. | Dissociation of mitochondrial HK-II elicits mitophagy and confers cardioprotection against ischemia | |
K Bhosle et al. | Nuclear localization of platelet-activating factor receptor controls retinal neovascularization | |
Cho et al. | STK3/STK4 signalling in adipocytes regulates mitophagy and energy expenditure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20171129 |